CannaPharmaRx scales sales but faces severe debt, impairments and Cease Trade Order

CannaPharmaRx, Inc. (PINK: CPMD)

Quick read: management is trying to scale sales (Germany/Israel focus) while the company struggles with heavy balance-sheet stress, related‑party financing, inventory impairments and a Cease Trade Order. There is ongoing forbearance with a major related‑party lender and a subsequent repayment plan announced in August 2025.

Key facts & statistics
* Cash: $16,975 (June 30, 2025) - up from $2,156 at 12/31/2024.
* Total assets: $11,472,755; Total liabilities: $34,046,840; Shareholders' deficit: $(22,574,085).
* Revenue: Q2 2025 $231,608; Six months 2025 $566,927 (2024 six months $25,839). Revenue sources: Cantek (related party) and Adjupharm (Germany).
* Cost of goods sold: Q2 2025 $852,818; six months $1,690,744. Inventory impairment included in COGS: Q2 $566,270; six months $1,046,203.
* Gross loss: Q2 $(621,210); six months $(1,123,817).
* Operating expenses (six months): $394,748 (down from $699,246 YoY due mainly to depreciation allocated to inventory and lower payroll/pro fees).
* Net loss: Q2 $(1,413,458); six months $(2,104,052). EPS: basic & diluted $(0.00) for six months.
* Inventory (net): $1,043,538 (finished goods $777,119; WIP $840,895 less impairments).
* Accounts payable & accrued liabilities: $10,012,932. Loans payable to related parties: $9,941,556. Accrued interest: $3,865,183.
* Convertible notes outstanding: $1,298,114; derivative conversion feature fair value: $564,051.
* Obligation to issue Class C preferred shares: $1,727,065 (contingent true‑up tied to revenue target).
* Right‑of‑use building (net): $5,627,215; lease liability total $6,097,660 (current portion $1,005,099).
* One‑time lease-related adjustment recorded: $1,930,000 (six months ended June 30, 2025).
* Cease Trade Order (BCSC) remains in place (filed for revocation; no assurance of lifting).
* Subsequent event (Aug 7, 2025): repayment plan with Koze & affiliates for ~ $10M debt; interest reset to 6% and 60% of future profits/capital allocated to repayment.

Positive points - what's working
* Revenue generation started and scaled from zero: six‑month revenues of $566,927, with export sales (Adjupharm) and related‑party sales (Cantek).
* Inventory and production base in place: 55,000 sq ft facility recommissioned; right‑of‑use asset $5.63M supports capacity expansion plans to 11 growing rooms.
* Non‑cash accounting items (fair value movements) provided large temporary volatility rather than immediate cash drains in some periods.
* Management secured related‑party financing and a formal repayment plan (Aug 2025) that reduces immediate interest pressure (6% going forward).

Negative points - income statement and financial health concerns
* High COGS and inventory write‑downs: six‑month impairment $1,046,203 - indicates product aging, market price pressure and poor margin recovery.
* Persistent losses: six‑month net loss $(2.10M); Q2 operating loss amplified by COGS and impairments.
* Cash burn and weak liquidity: operating cash used $1,047,844 in six months; cash balance only $16,975 and working capital deficiency $27.8M - substantial going‑concern doubt noted by management.
* Heavy related‑party debt and interest: loans payable to related parties $9.94M with significant accrued interest; interest expense large (six months $1,273,031).
* Significant current liabilities vs assets: accounts payable $10.01M vs current assets $1.20M - high short‑term pressure.
* Equity dilution and contingent obligations: obligation to issue preferred shares ($1.73M) tied to revenue milestones could dilute holders if targets hit; warrants outstanding 39,924,940 at $0.02 exercise.
* Operational risk and legal/insurance gaps: Cease Trade Order in Canada, lapsed insurance premiums, multiple legal claims (Ataraxia, BCI, Deloitte, former executives) and potential $15M/other claims exposure.
* Material weakness in internal control: management reports a material weakness due to turnover and record keeping - increases risk of misstatement or delayed reporting.

What to watch next
* Progress on lifting the CTO and on the Koze repayment plan implementation (Aug 2025 terms).
* Cash raising or refinancing events (equity or third‑party financing) - failure would likely force scaling down operations.
* Inventory turns, further impairments, and margin improvements from EU‑GMP progress or direct EU access.
* Related‑party exposure and any conversion or enforcement of security interests (Formosa/Koze) on the subsidiary.

Bottom line: CPMD has started commercial sales but is cash‑strained, loss‑making and heavily dependent on related‑party financing. The income statement shows revenue traction but is overwhelmed by high COGS, large inventory impairments and interest/lease costs. The August 2025 repayment plan eases interest rates but substantial liquidity, governance and legal risks remain.